T. Rowe Price Associates’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-28,234
| Closed | -$428K | – | 3040 |
|
|
2022
Q3 | $428K | Buy |
28,234
+12,519
| +80% | +$146K | ﹤0.01% | 2204 |
|
|
2022
Q2 | $118K | Buy |
15,715
+4,203
| +37% | +$29.6K | ﹤0.01% | 2724 |
|
|
2022
Q1 | $105K | Sell |
11,512
-1,892
| -14% | -$14.6K | ﹤0.01% | 2838 |
|
|
2021
Q4 | $94K | Sell |
13,404
-15,700
| -54% | -$164K | ﹤0.01% | 2886 |
|
|
2021
Q3 | $332K | Sell |
29,104
-201
| -0.7% | -$2.94K | ﹤0.01% | 2544 |
|
|
2021
Q2 | $469K | Buy |
29,305
+1,252
| +4% | +$21.5K | ﹤0.01% | 2416 |
|
|
2021
Q1 | $501K | Buy |
28,053
+52
| +0.2% | +$898 | ﹤0.01% | 2365 |
|
|
2020
Q4 | $378K | Buy |
28,001
+4,190
| +18% | +$50.6K | ﹤0.01% | 2353 |
|
|
2020
Q3 | $280K | Sell |
23,811
-6,041
| -20% | -$73.6K | ﹤0.01% | 2316 |
|
|
2020
Q2 | $441K | Buy |
29,852
+2,988
| +11% | +$44.2K | ﹤0.01% | 2097 |
|
|
2020
Q1 | $363K | Sell |
26,864
-324,489
| -92% | -$6.16M | ﹤0.01% | 2125 |
|
|
2019
Q4 | $8.49M | Sell |
351,353
-9,814
| -3% | -$203K | ﹤0.01% | 1339 |
|
|
2019
Q3 | $6.94M | Sell |
361,167
-3,876
| -1% | -$88.8K | ﹤0.01% | 1341 |
|
|
2019
Q2 | $10.8M | Buy |
365,043
+25
| +0% | +$963 | ﹤0.01% | 1303 |
|
|
2019
Q1 | $17.3M | Sell |
365,018
-2,122
| -0.6% | -$93.4K | ﹤0.01% | 1218 |
|
|
2018
Q4 | $13.3M | Buy |
367,140
+820
| +0.2% | +$38.5K | ﹤0.01% | 1258 |
|
|
2018
Q3 | $22.5M | Buy |
366,320
+5,974
| +2% | +$384K | ﹤0.01% | 1183 |
|
|
2018
Q2 | $24.3M | Buy |
360,346
+18,727
| +5% | +$1.05M | ﹤0.01% | 1142 |
|
|
2018
Q1 | $18.5M | Buy |
341,619
+13,948
| +4% | +$780K | ﹤0.01% | 1209 |
|
|
2017
Q4 | $19.6M | Buy |
327,671
+54,298
| +20% | +$3.29M | ﹤0.01% | 1199 |
|
|
2017
Q3 | $13.3M | Buy |
273,373
+41,971
| +18% | +$2.29M | ﹤0.01% | 1287 |
|
|
2017
Q2 | $12.2M | Sell |
231,402
-207,577
| -47% | -$9.66M | ﹤0.01% | 1284 |
|
|
2017
Q1 | $19.9M | Buy |
438,979
+412,309
| +1,546% | +$18.4M | ﹤0.01% | 1166 |
|
|
2016
Q4 | $1.01M | Buy |
26,670
+10
| +0% | +$378 | ﹤0.01% | 1779 |
|
|
2016
Q3 | $1.01M | Buy |
+26,660
| New | +$588K | ﹤0.01% | 1745 |
|
|
2014
Q4 | – | Sell |
-502,224
| Closed | -$10.4M | – | 2571 |
|
|
2014
Q3 | $10.4M | Buy |
+502,224
| New | +$9.9M | ﹤0.01% | 1298 |
|
T. Rowe Price Associates's AERI Position: Q4 2022 in Review
T. Rowe Price Associates sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 28,234 shares — an estimated $428K sold.
T. Rowe Price Associates first reported a position in AERI in Q3 2014 and held it in 26 quarters. The position peaked at $24.3M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- T. Rowe Price Associates reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- T. Rowe Price Associates sold 28,234 Aerie Pharmaceuticals shares in Q4 2022, an estimated $428K.
- T. Rowe Price Associates first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 26 quarters.
- T. Rowe Price Associates's Aerie Pharmaceuticals position peaked at $24.3M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.